Development of a nomogram for predicting radiation‑induced pneumonia in patients with lung cancer undergoing close‑range radiotherapy with radioactive <sup>125</sup>I particles

Ding,Tingting; Hao,Shanhu; Wang,Zhiguo; Zhang,Wenwen; Zhang,Guoxu

doi:10.3892/mco.2024.2797

Development of a nomogram for predicting radiation‑induced pneumonia in patients with lung cancer undergoing close‑range radiotherapy with radioactive ¹²⁵I particles

Authors:
- Tingting Ding
- Shanhu Hao
- Zhiguo Wang
- Wenwen Zhang
- Guoxu Zhang
View Affiliations

Affiliations: Department of Nuclear Medicine, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, P.R. China
Published online on: October 25, 2024 https://doi.org/10.3892/mco.2024.2797
Article Number: 2
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The most common and potentially fatal side effect of postoperative radiotherapy using radioactive ¹²⁵I particles in the chest is radiation‑induced pneumonia (RP). The present study aimed to develop a nomogram to accurately predict RP in patients with lung cancer following this type of radiotherapy. A retrospective analysis was conducted on data from 436 patients with advanced lung cancer who underwent close‑range radiotherapy using radioactive ¹²⁵I particles at the General Hospital of Northern Theater Command from January 2016 to December 2023 (Shenyang, China). Risk factors for RP were identified through least absolute shrinkage and selection operator logistic regression and multivariable logistic regression analysis. These factors were then used to construct a dynamic nomogram. The predictive performance of the nomogram was validated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis. Additionally, the grading of RP and Kaplan‑Meier analysis were performed. Preoperative N and M staging, the maximum dose and whether chemotherapy was administered were identified as significant predictors of RP. A dynamic nomogram for predicting RP was developed based on these risk factors. The area under the ROC curve was 0.878 (95% CI, 0.814‑0.942) for the training cohort and 0.828 (95% CI, 0.787‑0.870) for the validation cohort, indicating favorable discriminatory ability. The nomogram demonstrated excellent calibration. In both cohorts, the maximum dose parameter provided the most significant clinical benefits, supporting its promising clinical utility. Patients staged as T₁ and T₃ preoperatively were more likely to develop RP compared with those staged as T₂ (P<0.001). Likewise, patients staged as M1 preoperatively, those receiving a maximum dose above the mean, and those who had undergone chemotherapy exhibited a higher probability of developing RP (P<0.001). The developed nomogram offers a precise and user‑friendly tool for clinical application in predicting the risk of RP in patients with lung cancer undergoing close‑range radiotherapy with radioactive ¹²⁵I particles.

View Figures

View References

1	Huang M, Lin Q, Wang H, Chen J, Bai M, Wang L, Zhu K, Jiang Z, Guan S, Li Z, et al: Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: A retrospective matched cohort study. Eur Radiol. 26:3428–3436. 2016.PubMed/NCBI View Article : Google Scholar
2	Song J, Fan X, Zhao Z, Chen M, Chen W, Wu F, Zhang D, Chen L, Tu J and Ji J: ¹²⁵I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy: A comparison with best supportive care. Onco Targets Ther. 10:1345–1352. 2017.PubMed/NCBI View Article : Google Scholar
3	Yang DY, Lin YP, Xue C, Fan JM, Wang Y, Cai C, Song DH and Zeng YM: CT-guided percutaneous implantation of ¹²⁵I particles in treatment of early lung cancer. J Thorac Dis. 12:5996–6009. 2020.PubMed/NCBI View Article : Google Scholar
4	Wang H, Lu J, Zheng XT, Zha JH, Jing WD, Wang Y, Zhu GY, Zeng CH, Chen L and Guo JH: Oligorecurrence non-small cell lung cancer after failure of first-line chemotherapy: Computed tomography-guided ¹²⁵I seed implantation vs second-line chemotherapy. Front Oncol. 10(470)2020.PubMed/NCBI View Article : Google Scholar
5	Ji Z, Jiang Y, Guo F, Peng R, Sun H, Wang P, Fan J and Wang J: Radiation-related adverse effects of CT-guided implantation of ¹²⁵I seeds for thoracic recurrent and/or metastatic malignancy. Sci Rep. 9(14803)2019.PubMed/NCBI View Article : Google Scholar
6	Wang G, Zhang F, Yang B, Xue J, Peng S, Zhong Z, Zhang T, Lu M and Gao F: Feasibility and clinical value of CT-guided (125)I brachytherapy for bilateral lung recurrences from colorectal carcinoma. Radiology. 278:897–905. 2016.PubMed/NCBI View Article : Google Scholar
7	Su L, Dong Y, Wang Y, Wang Y, Guan B, Lu Y, Wu J, Wang X, Li D, Meng A and Fan F: Potential role of senescent macrophages in radiation-induced pulmonary fibrosis. Cell Death Dis. 12(527)2021.PubMed/NCBI View Article : Google Scholar
8	Cai G, Liang S, Li C, Meng X and Yu J: Left ventricular systolic dysfunction is a possible independent risk factor of radiation pneumonitis in locally advanced lung cancer patients. Front Oncol. 9(1511)2020.PubMed/NCBI View Article : Google Scholar
9	Simeonova AO, Fleckenstein K, Wertz H, Frauenfeld A, Boda-Heggemann J, Lohr F and Wenz F: Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy? Transl Lung Cancer Res. 1:45–53. 2012.PubMed/NCBI View Article : Google Scholar
10	Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, Zeng HM, Wei WW and He J: Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 46:221–231. 2024.PubMed/NCBI View Article : Google Scholar : (In Chinese).
11	Münsterberg J, Loreth D, Brylka L, Werner S, Karbanova J, Gandrass M, Schneegans S, Besler K, Hamester F, Robador JR, et al: ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium. Neuro Oncol. 22:955–966. 2020.PubMed/NCBI View Article : Google Scholar
12	Wang Y, Zhu L, Lin X, He C, An Z, Tang J, Lv W and Hu J: Therapeutic effect of CT-guided ¹²⁵I seed implantation on advanced lung cancer and pulmonary metastatic carcinoma. Zhongguo Fei Ai Za Zhi. 23:424–428. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
13	Wang X and Wang D: Clinical analysis of 125I seed implantation combined with epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. J BUON. 26:1879–1886. 2021.PubMed/NCBI
14	Zhang T, Lu M, Peng S, Zhang W, Yang G, Liu Z, Singh S, Yang Y, Zhang F and Gao F: CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy. J Cancer Res Clin Oncol. 140:1383–1390. 2014.PubMed/NCBI View Article : Google Scholar
15	Cao X, Fang L, Cui CY, Gao S and Wang TW: DTI and pathological changes in a rabbit model of radiation injury to the spinal cord after ¹²⁵I radioactive seed implantation. Neural Regen Res. 13:528–535. 2018.PubMed/NCBI View Article : Google Scholar
16	Zha Y, Zhang J, Yan X, Yang C, Wen L and Li M: A dynamic nomogram predicting symptomatic pneumonia in patients with lung cancer receiving thoracic radiation. BMC Pulm Med. 24(99)2024.PubMed/NCBI View Article : Google Scholar
17	De Petris L, Lax I, Sirzén F and Friesland S: Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer. Med Oncol. 22:375–381. 2005.PubMed/NCBI View Article : Google Scholar
18	Yu X, Li J, Zhong X and He J: Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy. BMC Cancer. 15(656)2015.PubMed/NCBI View Article : Google Scholar
19	Takeda A, Tsurugai Y, Sanuki N, Enomoto T, Shinkai M, Mizuno T, Aoki Y, Oku Y, Akiba T, Hara Y and Kunieda E: Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy. J Thorac Dis. 10:247–261. 2018.PubMed/NCBI View Article : Google Scholar
20	Bi J, Meng R, Yang D, Li Y, Cai J, Zhang L, Qian J, Xue X, Hu S, Yuan Z, et al: Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis. Radiother Oncol. 190(110040)2024.PubMed/NCBI View Article : Google Scholar
21	Ji Z, Ni Y, He C, Huo B, Liu S, Ma Y, Song Y, Hu M, Zhang K, Wang Z, et al: Clinical outcomes of radioactive seed brachytherapy and microwave ablation in inoperable stage I non-small cell lung cancer. Am J Cancer Res. 13:3753–3762. 2023.PubMed/NCBI
22	Flakus MJ, Kent SP, Wallat EM, Wuschner AE, Tennant E, Yadav P, Burr A, Yu M, Christensen GE, Reinhardt JM, et al: Metrics of dose to highly ventilated lung are predictive of radiation-induced pneumonitis in lung cancer patients. Radiother Oncol. 182(109553)2023.PubMed/NCBI View Article : Google Scholar
23	Huang P and Yi X: Risk factors and a model for prognosis prediction after intravenous thrombolysis with alteplase in acute ischemic stroke based on propensity score matching. Int J Immunopathol Pharmacol. 38(3946320241274231)2024.PubMed/NCBI View Article : Google Scholar